A5081920237- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Autoimmune and Inflammatory Disorders Research
- Dental Implant Techniques and Outcomes
- Dental materials and restorations
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Systemic Lupus Erythematosus Research
- Bone and Joint Diseases
- Systemic Sclerosis and Related Diseases
- Esophageal and GI Pathology
- Dental Research and COVID-19
- Salivary Gland Disorders and Functions
- Biliary and Gastrointestinal Fistulas
- Dermatology and Skin Diseases
- Dental Health and Care Utilization
- Inflammatory Bowel Disease
- Gastric Cancer Management and Outcomes
- Peripheral Neuropathies and Disorders
- Osteomyelitis and Bone Disorders Research
- Spine and Intervertebral Disc Pathology
- Oral microbiology and periodontitis research
- Temporomandibular Joint Disorders
- Hematological disorders and diagnostics
- Bone Tissue Engineering Materials
University Hospital Heidelberg
2013-2025
Heidelberg University
2013-2023
Goethe University Frankfurt
2015-2021
German Rheumatism Research Centre
2003-2019
Collegium Carolinum
2019
Charité - Universitätsmedizin Berlin
2004-2016
University of Rostock
2008-2009
Rostocker Zentrum zur Erforschung des Demografischen Wandels
2009
Center for Rheumatology
2009
University of Zurich
2009
<h3>Objective:</h3> To validate and refine two sets of candidate criteria for the classification/diagnosis axial spondyloarthritis (SpA). <h3>Methods:</h3> All Assessment SpondyloArthritis international Society (ASAS) members were invited to include consecutively new patients with chronic (⩾3 months) back pain unknown origin that began before 45 years age. The first tested in entire cohort 649 from 25 centres, then refined a random selection 40% cases thereafter validated remaining 60%....
The ESC Guidelines represent the views of and were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient, where necessary patient's guardian or carer.It is also professional's verify rules regulations...
Distinguishing true cellulitis from its many imitators is challenging but critical if we are to avoid unnecessary use of antibiotics and delays in treatment. Common stasis dermatitis, lipodermatosclerosis, contact lymphedema, eosinophilic cellulitis, papular urticaria. Specific criteria do not exist for the diagnosis alert physician can find clues history physical examination that point toward cellulitis.
The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition outcome parameters for clinical trials. In present work, Assessment SpondyloArthritis international Society (ASAS) provides comprehensive handbook on most relevant aspects assessments spondyloarthritis, covering classification criteria, MRI <i>x</i> rays sacroiliac joints spine, complete set all...
<h3>Objective:</h3> Non-radiographic axial spondyloarthritis (SpA) is characterised by a lack of definitive radiographic sacroiliitis and considered an early stage ankylosing spondylitis. The objective this study was to develop candidate classification criteria for SpA that include patients with but also without sacroiliitis. <h3>Methods:</h3> Seventy-one possible SpA, most whom were lacking definite sacroiliitis, reviewed as "paper patients" 20 experts from the Assessment SpondyloArthritis...
Inflammatory back pain (IBP) is an important clinical symptom in patients with axial spondyloarthritis (SpA), and relevant for classification diagnosis. In the present report, a new approach development of IBP criteria discussed.Rheumatologists (n = 13) who are experts SpA took part 2-day international workshop to investigate 20 possible SpA. Each expert documented presence/absence parameters typical IBP, judged whether was considered or absent based on received information. This judgement...
Objective Tumor necrosis factor α (TNFα) has been detected in sacroiliac joint biopsy specimens from patients with spondylarthropathy. The present open pilot study was undertaken to test the efficacy of anti-TNFα monoclonal antibody infliximab treatment active ankylosing spondylitis (AS). Methods Eleven AS short duration (median 5 years, range 0.5–13 years) that had for at least 3 months (range 3–72 months) were treated infusions (at weeks 0, 2, and 6), a dosage mg/kg. Ten 11 elevated...
Abstract Objective There is increasing evidence that tumor necrosis factor α (TNFα) centrally involved in the pathogenesis of ankylosing spondylitis (AS) and other spondylarthritides. This study was designed to investigate efficacy anti‐TNFα therapy with etanercept, a 75‐kd receptor fusion protein, active AS. Methods multicenter trial had 2 phases: an initial placebo‐controlled period 6 weeks' duration observational phase lasting 24 weeks. Thirty patients AS were included. They randomized...
Abstract Objective To evaluate a magnetic resonance imaging (MRI) scoring system for the assessment of spinal inflammation in patients with ankylosing spondylitis (AS) who participated randomized, placebo‐controlled trial infliximab, and to examine whether infliximab is also effective reduction MRI‐proven inflammation. Methods Twenty AS (9 women 11 men, mean age 40.9 years) were examined at baseline after 3 months. Nine had received infusions (5 mg/kg body weight) weeks 0, 2, 6, placebo....
Abstract Objective Treatment of ankylosing spondylitis (AS) with infliximab, an anti–tumor necrosis factor α monoclonal antibody, was shown to be efficacious in patients active disease during a 3‐month treatment period. The purpose this study evaluate the efficacy and safety infliximab AS for 1‐year Methods This open, observational, extension 3‐month, randomized, placebo‐controlled trial. All who had tolerated (infliximab/infliximab group) or placebo (placebo/infliximab 12‐week crossover...
Structural changes such as erosions, syndesmophytes and ankylosis are characteristic of ankylosing spondylitis (AS). These can be quantified by the modified Stokes Anklylosing Spondylitis Spinal Score (mSASSS). It is unknown which radiographic feature most relevant for assessment change prediction future damage in AS.To analyse progression AS using different assessments to define important changes.Spinal radiographs 116 patients with were scored mSASSS at baseline (BL) after 2 years....
Abstract We analyzed the clinical response and time to relapse after discontinuation of continuous long-term infliximab therapy in patients with ankylosing spondylitis (AS). After 3 years therapy, all AS ( n = 42) discontinued treatment (time point (TP)1) were visited regularly for 1 year order assess (TP2). Relapse was defined as an increase a value ≥ 4 on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) physician's global assessment according recommendations Assessments (ASAS)...
<b>Objective:</b> To develop and compare candidate improvement criteria for anti-TNFα treatment in ankylosing spondylitis with optimal discriminating capacity between placebo. <b>Methods:</b> Data from two randomised controlled trials which included 99 patients treated infliximab or etanercept were used to evaluate 50 criteria. These developed on the basis of pain, patient’s global assessment, function, morning stiffness, spinal mobility, C reactive protein. Different levels each domain...
<h3>Objective</h3> To study the relationship of spinal inflammation and fatty degeneration (FD) as detected by MRI new bone formation seen on conventional radiographs (CRs) in ankylosing spondylitis (AS). <h3>Methods</h3> CRs at baseline, 2 years 5 MRIs baseline 73 AS patients treated with infliximab European Infliximab Cohort were available. Relative risks (RR) calculated a general linear model after adjustment for within-patient variation. <h3>Results</h3> In total 1466 vertebral edges...
Objective. Infliximab, a monoclonal antibody against tumour necrosis factor α (TNF-α), is approved in Europe for the treatment of patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. This report provides analyses from 3-yr extension study, as follow-up both 1- and 2-yr open label extensions original 3-month randomized controlled trial infliximab AS.
Objectives. Anti-tumour necrosis factor therapy with infliximab has been shown to improve signs and symptoms of patients active ankylosing spondylitis (AS). The objective this article was study the effect on structural changes in AS over 4 yrs. Methods. Conventional radiographs cervical lumbar spine 33 at baseline (BL), after 2 (FU1) yrs (FU2) were scored by modified Stokes spinal score (mSASSS). Definite damage defined when least one syndesmophyte (mSASSS ≥2) seen. radiographic progression...
<b>Objectives:</b> To assess the effect of sulfasalazine (SSZ) on inflammatory back pain (IBP) due to active undifferentiated spondyloarthritis (uSpA) or ankylosing spondylitis in patients with symptom duration <5 years. <b>Methods:</b> Patients IBP and a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >3 from 12 centres were randomly assigned 24 weeks' treatment SSZ 2 g/day placebo. The primary outcome variable was change BASDAI over 6 months. Secondary outcomes included...
Objectives The Assessment of SpondyloArthritis International Society (ASAS) aimed to develop a set quality standards (QS) help improve the healthcare provided adult patients affected by axial spondyloarthritis (axSpA) worldwide. Methods An ASAS task force developed QS using stepwise approach. First, key areas for improvement were identified, discussed, rated and agreed on. Thereafter, prioritised statements most important phrased on consensus. Appropriate measures defined allow...
<b>Objective:</b> To obtain results of the second year extension an original 3 month randomised, placebo controlled trial (and 1 study) assessing use infliximab, a monoclonal antibody to tumour necrosis factor α, for treatment patients with ankylosing spondylitis (AS). <b>Methods:</b> Of 54 AS who completed first study, 52 continued receive infliximab 5 mg/kg every 6 weeks up week 102. The primary end point was proportion achieving at least 50% improvement from baseline in Bath Disease...
Abstract Objective To examine the long‐term outcome of patients with active ankylosing spondylitis (AS) clinically and by magnetic resonance imaging (MRI) after continuous treatment tumor necrosis factor (TNF) receptor fusion protein etanercept over 2 years. Methods Overall, 26 AS were treated 25 mg twice daily subcutaneously, weekly no concomitant disease‐modifying antirheumatic drugs (DMARDs) or steroids. The clinical response was assessed standardized parameters. Inflammatory spinal...
Objectives. Treatment of ankylosing spondylitis (AS) with the tumour necrosis factor α (TNF-α) receptor fusion protein etanercept has shown efficacy in patients active disease randomized controlled trials (RCTs) for limited periods. The objective study was to assess long-term and safety over 1 yr, including discontinuation readministration.
Objectives. Patients with ankylosing spondylitis (AS) benefit from anti-TNF therapy both on a clinical basis and as depicted by magnetic resonance imaging (MRI). It is not known whether spinal inflammation remains suppressed over time. Our objective was to assess MRI in AS patients after 2 yr of continuous infliximab treatment. Methods. Twenty active were examined at baseline, 3 months (end placebo-controlled-phase) (5 mg/kg/6 weeks). T1 pre- post-gadolinium...